Innoviva/$INVA
1D1W1MYTD1Y5YMAX
Capital at risk
About Innoviva
Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.
- Ticker
- $INVA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 159
- Headquarters
- Burlingame, United States
- Website
- www.inva.com
Innoviva Metrics
BasicAdvanced
$1.5B
4.80
$4.31
0.34
-
Price and volume
Market cap
$1.5B
Beta
0.34
52-week high
$25.15
52-week low
$16.52
Average daily volume
680K
Financial strength
Current ratio
16.007
Quick ratio
14.654
Long term debt to equity
26.29
Total debt to equity
26.859
Interest coverage (TTM)
9.26%
Profitability
EBITDA (TTM)
195.387
Gross margin (TTM)
72.67%
Net profit margin (TTM)
81.19%
Operating margin (TTM)
38.36%
Effective tax rate (TTM)
14.82%
Revenue per employee (TTM)
$2,770,000
Management effectiveness
Return on assets (TTM)
6.95%
Return on equity (TTM)
36.68%
Valuation
Price to earnings (TTM)
4.795
Price to revenue (TTM)
3.423
Price to book
1.22
Price to tangible book (TTM)
1.43
Price to free cash flow (TTM)
8.363
Free cash flow yield (TTM)
11.96%
Free cash flow per share (TTM)
2.47
Growth
Revenue change (TTM)
18.84%
Earnings per share change (TTM)
708.30%
3-year revenue growth (CAGR)
14.85%
10-year revenue growth (CAGR)
16.81%
3-year earnings per share growth (CAGR)
17.64%
10-year earnings per share growth (CAGR)
38.60%
What the Analysts think about Innoviva
Analyst ratings (Buy, Hold, Sell) for Innoviva stock.
Analyst projections of the future price of Innoviva stock.
Bulls say / Bears say
IST net product sales grew 46% year-over-year to $51.8 million in Q2 2026, including 26% growth in U.S. sales to $36.6 million, demonstrating strong commercial momentum in critical care and infectious disease (TradingView News)
Royalty revenue remained resilient at $59.8 million in Q2 2026, providing stable and durable cash flow from GSK-partnered respiratory products (TradingView News)
Repurchased 1.4 million shares for $31.4 million in Q2 under its $125 million buyback program, underscoring management’s confidence in Innoviva’s intrinsic value (TradingView News)
Reported a net loss of $83.4 million in Q2 2026, driven primarily by a $161.0 million markdown in fair value of equity and long-term investments, highlighting volatility in its strategic asset portfolio (TradingView News)
As of February 2026, Moody’s downgraded Innoviva’s senior unsecured debt rating to Ba2 with a negative outlook, and S&P and Fitch cut theirs to BB with negative outlooks, leaving Innoviva’s debt non-investment grade and increasing its borrowing costs (SEC Q1 2026 10-Q)
GSK’s Q2 2026 respiratory sales fell 10% on a constant exchange rate basis, with Relvar/Breo Ellipta down 13% and Trelegy Ellipta down 7%, posing downside risk to Innoviva’s royalty streams (Reuters via TradingView)
Data summarised monthly by Lightyear AI. Last updated on 29 Aug 2026.
Innoviva Financial Performance
Revenues and expenses
Innoviva Earnings Performance
Company profitability
Upcoming events
No upcoming events
Innoviva News
AllArticlesVideos
Funds containing Innoviva
AllUSDGBPEUR
Fund name | Fund size | $INVA weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.11% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.11% |
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.08% |
iShares S&P Small Cap 600£ISP6 | £2.4B | 0.08% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.05% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.